MCI1
MCID: MYC007
MIFTS: 68

Myocardial Infarction (MCI1)

Categories: Cardiovascular diseases, Genetic diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Myocardial Infarction

MalaCards integrated aliases for Myocardial Infarction:

Name: Myocardial Infarction 57 11 28 53 5 43 14 36 16 71 75
Heart Attack 11 75 41 14 63
Myocardial Infarction, Susceptibility to 57 28 12 5
Myocardial Infarction 1 73 28 5
Myocardial Infarction, Decreased Susceptibility to 57 5
Myocardial Infarction, Protection Against 57 5
Myocardial Infarction, Susceptibility to, Type 1 38
Myocardial Infarction, Decreased 57
Premature Myocardial Infarction 73
Myocardial Infarct 11
Mci1 73

Classifications:



External Ids:

Disease Ontology 11 DOID:5844
OMIM® 57 608446
MeSH 43 D009203
NCIt 49 C27996
SNOMED-CT 68 66514008
ICD10 31 I21
UMLS 71 C0027051

Summaries for Myocardial Infarction

MedlinePlus: 41 Each year almost 800,000 Americans have a heart attack. A heart attack happens when blood flow to the heart suddenly becomes blocked. Without the blood coming in, the heart can't get oxygen. If not treated quickly, the heart muscle begins to die. But if you do get quick treatment, you may be able to prevent or limit damage to the heart muscle. That's why it's important to know the symptoms of a heart attack and call 911 if you or someone else is having them. You should call, even if you are not sure that it is a heart attack. The most common symptoms in men and women are: Chest discomfort. It is often in center or left side of the chest. It usually lasts more than a few minutes. It may go away and come back. It can feel like pressure, squeezing, fullness, or pain. It also can feel like heartburn or indigestion. Shortness of breath. Sometimes this is your only symptom. You may get it before or during the chest discomfort. It can happen when you are resting or doing a little bit of physical activity. Discomfort in the upper body. You may feel pain or discomfort in one or both arms, the back, shoulders, neck, jaw, or upper part of the stomach. You may also have other symptoms, such as nausea, vomiting, dizziness, and lightheadedness. You may break out in a cold sweat. Sometimes women will have different symptoms then men. For example, they are more likely to feel tired for no reason. The most common cause of heart attacks is coronary artery disease (CAD). With CAD, there is a buildup of cholesterol and other material, called plaque, on their inner walls or the arteries. This is atherosclerosis. It can build up for years. Eventually an area of plaque can rupture (break open). A blood clot can form around the plaque and block the artery. A less common cause of heart attack is a severe spasm (tightening) of a coronary artery. The spasm cuts off blood flow through the artery. At the hospital, health care providers make a diagnosis based on your symptoms, blood tests, and different heart health tests. Treatments may include medicines and medical procedures such as coronary angioplasty. After a heart attack, cardiac rehabilitation and lifestyle changes can help you recover. NIH: National Heart, Lung, and Blood Institute

MalaCards based summary: Myocardial Infarction, also known as heart attack, is related to lipoprotein quantitative trait locus and cardiovascular system disease, and has symptoms including angina pectoris, chest pain and edema. An important gene associated with Myocardial Infarction is MIAT (Myocardial Infarction Associated Transcript), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Antiviral and anti-inflammatory effects of Nrf2 on SARS-CoV-2 pathway. The drugs Miconazole and Clotrimazole have been mentioned in the context of this disorder. Affiliated tissues include Bone and Limb.

PubMed Health : 63 Heart attack: A heart attack happens when the flow of oxygen-rich blood to a section of heart muscle suddenly becomes blocked and the heart can't get oxygen. If blood flow isn't restored quickly, the section of heart muscle begins to die. Heart attacks are a leading killer of both men and women in the United States. The good news is that excellent treatments are available for heart attacks. These treatments can save lives and prevent disabilities. Heart attack treatment works best when it's given right after symptoms occur. If you think you or someone else is having a heart attack (even if you're not fully sure), call 9–1–1 right away.

Disease Ontology: 11 A coronary artery disease characterized by myocardial cell death (myocardial necrosis) due to prolonged ischaemia.

UniProtKB/Swiss-Prot: 73 A condition defined by the irreversible necrosis of heart muscle secondary to prolonged ischemia.

Wikipedia: 75 A myocardial infarction (MI), commonly known as a heart attack, occurs when blood flow decreases or... more...

More information from OMIM: 608446

Related Diseases for Myocardial Infarction

Diseases in the Myocardial Infarction family:

Myocardial Infarction 2 Posterior Myocardial Infarction
Acute Myocardial Infarction

Diseases related to Myocardial Infarction via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1753)
# Related Disease Score Top Affiliating Genes
1 lipoprotein quantitative trait locus 33.3 OLR1 MIR210 MIR21 LGALS2 ITGB3 F7
2 cardiovascular system disease 32.9 OLR1 MIR210 MIR21 F7 ESR1 CDKN2B-AS1
3 stroke, ischemic 32.7 OLR1 MIR21 MIAT F7 CDKN2B-AS1
4 diabetes mellitus 32.5 OLR1 MIR210 MIR21 LTA F7 ESR1
5 thrombophilia 31.7 ITGB3 F7 F13A1
6 alzheimer disease, familial, 1 31.0 OLR1 MIR210 MIR21 MIAT LRP8 CDKN2B-AS1
7 bone disease 30.7 MIR210 MIR21 LTA ESR1
8 cerebral palsy 30.1 LTA ITGB3 F7 CLCN1
9 acute myocardial infarction 12.2
10 inferior myocardial infarction 11.7
11 coronary artery disease, autosomal dominant, 1 11.7
12 anterolateral myocardial infarction 11.6
13 myocardial infarction 2 11.6
14 ventricular fibrillation, paroxysmal familial, 1 11.6
15 cardiogenic shock 11.5
16 posterior myocardial infarction 11.5
17 silent myocardial infarction 11.5
18 anteroseptal myocardial infarction 11.5
19 angina pectoris 11.5
20 cardiac rupture 11.5
21 hyperlipoproteinemia, type iii 11.5
22 septal myocardial infarction 11.5
23 subendocardial myocardial infarction 11.5
24 coronary heart disease 1 11.5
25 acute anterolateral myocardial infarction 11.4
26 coronary thrombosis 11.4
27 acute inferolateral myocardial infarction 11.4
28 lateral myocardial infarction 11.4
29 intermediate coronary syndrome 11.4
30 apical myocardial infarction 11.4
31 posterolateral myocardial infarction 11.4
32 atherosclerosis susceptibility 11.4
33 posteroinferior myocardial infarction 11.3
34 inferolateral myocardial infarct 11.3
35 dressler's syndrome 11.3
36 subendocardial infarction acute myocardial infarction 11.3
37 strictly posterior acute myocardial infarction 11.3
38 congestive heart failure 11.3
39 coronary artery dissection, spontaneous 11.3
40 kawasaki disease 11.3
41 heart disease 11.3
42 morbid obesity and spermatogenic failure 11.3
43 thrombomodulin anomalies, familial 11.3
44 progressive familial heart block, type ia 11.2
45 progressive familial heart block 11.2
46 cardiac arrest 11.2
47 arteries, anomalies of 11.2
48 cardiac conduction defect 11.2
49 acute inferoposterior infarction 11.2
50 conn's syndrome 11.2

Graphical network of the top 20 diseases related to Myocardial Infarction:



Diseases related to Myocardial Infarction

Symptoms & Phenotypes for Myocardial Infarction

Clinical features from OMIM®:

608446 (Updated 24-Oct-2022)

UMLS symptoms related to Myocardial Infarction:


angina pectoris; chest pain; edema

Drugs & Therapeutics for Myocardial Infarction

PubMed Health treatment related to Myocardial Infarction: 63

Early treatment for a heart attack can prevent or limit damage to the heart muscle . Acting fast, at the first symptoms of a heart attack, can save your life. Medical personnel can begin diagnosis and treatment even before you get to the hospital. Certain treatments usually are started right away if a heart attack is suspected, even before the diagnosis is confirmed. These include: Oxygen therapy Aspirin to thin your blood and prevent further blood clotting Nitroglycerin to reduce your heart 's workload and improve blood flow through the coronary arteries Treatment for chest pain Once the diagnosis of a heart attack is confirmed or strongly suspected, doctors start treatments to try to promptly restore blood flow to the heart. The two main treatments are "clot-busting" medicines and percutaneous coronary intervention (PCI), sometimes referred to as coronary angioplasty , a procedure used to open blocked coronary arteries .

Drugs for Myocardial Infarction (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 528)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
2
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
3
Etanercept Approved, Investigational Phase 4 185243-69-0
4
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
5
Perindopril Approved Phase 4 82834-16-0, 107133-36-8 107807
6
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 2713 9552079
7
Sotalol Approved Phase 4 959-24-0, 3930-20-9 5253
8
Amiodarone Approved, Investigational Phase 4 1951-25-3 2157
9
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
10
Metformin Approved Phase 4 1115-70-4, 657-24-9 4091
11
Atenolol Approved Phase 4 29122-68-7 2249
12
Streptokinase Approved, Investigational Phase 4 9002-01-1
13
Pravastatin Approved Phase 4 81093-37-0 54687
14
Morphine Approved, Investigational Phase 4 57-27-2 5288826
15
Simvastatin Approved Phase 4 79902-63-9 54454
16
Eptifibatide Approved, Investigational Phase 4 188627-80-7 448812
17
Reteplase Approved, Investigational Phase 4 133652-38-7
18
Bivalirudin Approved, Investigational Phase 4 128270-60-0 19797045 16129704
19
Eplerenone Approved Phase 4 107724-20-9 443872
20
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
21
Tirofiban Approved Phase 4 144494-65-5 60947
22
Thrombin Approved, Investigational Phase 4
23
Alprostadil Approved, Investigational Phase 4 745-65-3 5280723
24
Zinc cation Approved, Experimental, Investigational Phase 4 7440-66-6, 23713-49-7 32051
25
Insulin glargine Approved Phase 4 160337-95-1 118984454
26
Verapamil Approved Phase 4 152-11-4, 52-53-9 2520
27
Acetylcysteine Approved, Investigational Phase 4 616-91-1 581 12035
28
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
29
Racepinephrine Approved, Vet_approved Phase 4 51-43-4, 329-65-7 838 5816
30
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
31
Hydroxychloroquine Approved Phase 4 118-42-3 3652
32
Exenatide Approved, Investigational Phase 4 141758-74-9 45588096
33
Methylnaltrexone Approved Phase 4 916055-93-1 5361918
34
Bilberry Approved, Experimental Phase 4
35
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
36 Apricot Approved Phase 4
37
Saxagliptin Approved Phase 4 361442-04-8 11243969
38
Edaravone Approved, Investigational Phase 4 89-25-8 70335 4021
39
Insulin lispro Approved Phase 4 133107-64-9 16132438
40
Famotidine Approved Phase 4 76824-35-6 3325 5702160
41
Bezafibrate Approved, Investigational Phase 4 41859-67-0 39042
42
Vorapaxar Approved Phase 4 618385-01-6 72455102 10077130
43
Aminophylline Approved Phase 4 317-34-0 9433
44
Erythromycin Approved, Investigational, Vet_approved Phase 4 55-31-2, 114-07-8 12560
45
Ibuprofen Approved Phase 4 15687-27-1 3672
46
Lisinopril Approved, Investigational Phase 4 83915-83-7, 76547-98-3 5362119
47
Bupropion Approved Phase 4 31677-93-7, 34841-39-9, 34911-55-2 444
48
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
49
Magnesium oxide Approved Phase 4 1309-48-4 14792
50
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603

Interventional clinical trials:

(show top 50) (show all 2526)
# Name Status NCT ID Phase Drugs
1 Assessment of Coronary Flow Reserve by Doppler Flow WIre in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Differences Between the Loading Dose of Prasugrel and Ticagrelor . Unknown status NCT02032303 Phase 4 Ticagrelor loading;Prasugrel loading
2 Assessment of Coronary Flow Reserve by Doppler Flow Wire in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Differences Between the Loading Dose of Ticagrelor and Clopidogrel Unknown status NCT02032290 Phase 4 ticagrelor loading;Clopidogrel loading
3 Pravastatin for Acute Myocardial Infarction With Minimally to Mildly Increased Levels of Serum Cholesterol Study That Evaluates the Effects of Pravastatin for Acute Myocardial Infarction With LDL-Cholesterol Levels of 70-129 mg/dl Unknown status NCT00688922 Phase 4 Pravastatin
4 Role of Innate and Adaptive Immunity After Acute Myocardial Infarction BATTLE-AMI Study (B And T Types of Lymphocytes Evaluation in Acute Myocardial Infarction) Unknown status NCT02428374 Phase 4 Rosuvastatin plus clopidogrel;Rosuvastatin plus ticagrelor;Simvastatin plus clopidogrel;Simvastatin plus ticagrelor
5 Cangrelor vs. Ticagrelor for Early Platelet Inhibition in ST-elevation Myocardial Infarction Unknown status NCT03182855 Phase 4 Ticagrelor;Cangrelor Tetrasodium
6 A Developmental Clinical Study of Management Guided by Coronary Angiography Combined With Fractional Flow Reserve (FFR) Measurement Versus Management Guided by Coronary Angiography Alone(Standard Care) in Patients With Non-ST Elevation MI. Unknown status NCT01764334 Phase 4
7 Effects of Salvianolate Injection on Myocardial Microcirculation in Patients With Acute ST Segment Elevation Myocardial Infarction After Primary PCI Unknown status NCT03045562 Phase 4 Normal saline;Salvianolate injection
8 The Effects of Morphine on Loading-dose Ticagrelor in Patients With ST-segment Elevation Myocardial Infarction Before Primary Percutaneous Coronary Interven Tion Unknown status NCT02913469 Phase 4 Morphine;metoclopramide;saline
9 Bare Metal Stent Versus Drug Coated Balloon With Provisional Stenting in Non-ST-Elevation Myocardial Infarction Unknown status NCT01489449 Phase 4
10 Coronary Angioplasty in Octogenarians With Emergent Coronary Syndromes: The Octogenarians Study Unknown status NCT02126202 Phase 4
11 Bivalirudin vs Heparin in Elderly Patients With Acute ST-segment Elevation Myocardial Infarction Undergoing Emergency Percutaneous Coronary Intervention Unknown status NCT03882775 Phase 4 Bivalirudin;Heparin
12 Safety and Efficacy of Thrombus Aspiration in Patients With ST-segment Elevation Myocardial Infarction (STEMI) Unknown status NCT02606435 Phase 4
13 A Prospective Evaluation of a Standardized Strategy for the Use of Bioresorbable Vascular Scaffold in ST-segment Elevation Myocardial Infarction: the BVS STEMI STRATEGY-IT Registry Unknown status NCT02601781 Phase 4
14 Bivalirudin Plus Prasugrel vs Abciximab Plus Clopidogrel. Optimizing Ischemic Protection and Bleeding Risk in Patients With ST Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention Unknown status NCT01158846 Phase 4 prasugrel/bivalirudin;clopidogrel/abciximab
15 Comparison of The Influence of Ticagrelor And Clopidogrel on Inflammatory Biomarkers And Vascular Endothelial Function For Patients With ST-Segment Elevation Myocardial Infarction Receiving Emergency Percutaneous Coronary Intervention Unknown status NCT02123004 Phase 4 Ticagrelor;Clopidogrel
16 Intracoronary Cocktail Injection Combined With Thrombus Aspiration in ST-elevation Myocardial Infarction Patients Treated With Primary Angioplasty Unknown status NCT02592694 Phase 4 cocktail
17 The Efficiency and Safety of Bivalirudin in latE percuTaneous Coronary inTervention for Patients With ST-Elevation Myocardial InfaRction (BETTER Trial) Unknown status NCT04185077 Phase 4 Bivalirudin;Heparin
18 Thrombus Aspiration During Percutaneous Coronary Intervention in Acute Non-ST-elevation Myocardial Infarction Study (TAPAS II) Unknown status NCT01013038 Phase 4
19 High PlatElet Inhibition With TicAgrelor to Improve Left Ventricular RemodeLING in Patients With ST-segment ElevAtion Myocardial Infarction: the HEALING-AMI Trial. Unknown status NCT02224534 Phase 4 Ticagrelor;Clopidogrel
20 Early Initiation of Low Dose Tirofiban for Primary Percutaneous Coronary Intervention in Patients With ST-segment Elevation Myocardial Infarction. Unknown status NCT03797729 Phase 4 Tirofiban;Normal saline
21 A Randomized Trial to Compare Four Different Intracoronary Modalities to Reduce Thrombus Burden and Improve Microcirculatory Function in Patients With ST-elevation Myocardial Infarction: Rationale and Design of the COCTAIL II Study Unknown status NCT01499407 Phase 4 Abciximab
22 Multivessel Stenting and Staged Revascularization for ST-elevation Myocardial Infarction Patients With Resolute Integrity Stents Unknown status NCT01781715 Phase 4
23 Study of Anti-inflammatory Treatment With Colchicine in the Acute Phase of ST-elevation Myocardial Infarction to Reduce Infarct Size Unknown status NCT01936285 Phase 4 Colchicine 2 mg loading dose; 0.5 mg bid for 5 days;Placebo
24 Effects of Intensive Statin Therapy on Left Ventricular Function for Patients With the First Acute Anterior Myocardial Infarction After Directly to Percutaneous Coronary Intervention. Unknown status NCT01936103 Phase 4 standard group;intensive group
25 Efficacy of Intracoronary Infusion of Different Medicine With Targeted Perfusion Catheter on Myocardial Perfusion in Patients With STEMI Undergoing Primary PCI:an Open,Prospective,Randomized,Multicenter Trial. Unknown status NCT03252665 Phase 4 Alprostadil;Nicorandil;Nitroglycerin
26 Ticagrelor or Prasugrel Versus Clopidogrel in Elderly Patients With an Acute Coronary Syndrome and a High Bleeding Risk: Optimization of Antiplatelet Treatment in High-risk Elderly Unknown status NCT02317198 Phase 4 Clopidogrel;Ticagrelor or Prasugrel
27 Reducing Micro Vascular Dysfunction In Revascularized ST-elevation Myocardial Infarction Patients by Off-target Properties of Ticagrelor Unknown status NCT02422888 Phase 4 Ticagrelor;Prasugrel
28 Effect of Early Administration of Intracoronary Nicorandil Via Thrombus Aspiration Catheter Device During Primary Percutaneous Coronary Intervention for the Patients of Acute ST Segment Elevation Myocardial Infarction Unknown status NCT02435797 Phase 4 Nicorandil;normal saline
29 Randomized, Prospective , Open Label, Phase 4 Trial of Efficacy and Safety of Adjunctive Cilostazol in Acute Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention With Drug-eluting Stent Unknown status NCT01261832 Phase 4 antiplatelet therapy
30 A Randomized Clinical Trial Comparing Primary PCI and Post-thrombolysis PCI as Reperfusion Strategies in Patients With ST Segment Elevation Acute Myocardial Infarction Unknown status NCT02268669 Phase 4
31 Efficacy of Thrombosuction in Primary Percutaneous Coronary Intervention of Acute Myocardial Infarction Unknown status NCT01156662 Phase 4
32 The Safety and Efficacy of Etanercept in Treating Patient With Acute ST Segment Elevated Myocardial Infarction Unknown status NCT01372930 Phase 4 Etanercept;saline
33 Immediate Versus Delayed Stenting in Patients With ST-Elevation Myocardial Infarction Undergoing Mechanical Intervention Unknown status NCT01462188 Phase 4
34 Chewing Ticagrelor Versus Prasugrel in ST-elevation Myocardial Infarction - A Platelet Reactivity Study Unknown status NCT03016611 Phase 4 Chewing Ticagrelor LD;Chewing Prasugrel LD
35 Microvascular Reperfusion Utilizing Sonothrombolysis in Acute Myocardial Infarction (MRUSMI TRIAL) Unknown status NCT02170103 Phase 4 Microbubbles
36 Prospective Observational Clinical Study:The Impact of Early rhBNP on Myocardial Remodeling and Reperfusion in Patients With ST-segment Elevation Myocardial Infarction After Percutaneous Coronary Intervention Unknown status NCT04033861 Phase 4 rhBNP;Control
37 Intracoronary Bolus Only Compared With Intravenous Bolus and 12-hours Infusion of Abciximab in Non-ST Elevation Myocardial Infarction. Unknown status NCT01080638 Phase 4 glycoprotein IIb/IIIa inhibitor (abciximab)
38 Randomized Study Of Sirolimus Eluting Stent Vs Conventional Stent In Acute Myocardial Infarction Acronym SESAMI Unknown status NCT00288210 Phase 4
39 Pharmacokinetic/Pharmacodynamic Effects of add-on Antiplatelet Therapy With Parenteral Cangrelor as Compared to Standard Dual Antiplatelet Treatment in Patients With ST-elevation Myocardial Infarction Complicated by Out-of-hospital Cardiac Arrest and Treated With Targeted Temperature Management Unknown status NCT03273075 Phase 4 Cangrelor;Placebo;Prasugrel;Ticagrelor
40 Ticagrelor Versus Clopidogrel in Myocardial Salvage in Patients With ST-elevation Myocardial Infarction (STEMI) Undergoing Primary Percutaneous Coronary Intervention: A Magnetic Resonance Imaging Study (TIGER Study) Unknown status NCT02792712 Phase 4 Ticagrelor;Clopidogrel
41 Prospective RandomizEd Study Comparing Glycoprotein IIb/IIIa Inhibitors VERsus Standard Therapy in patientS With Myocardial Infarction and Angiographic Evidence of No-reFLOW Unknown status NCT02739711 Phase 4 Glycoprotein IIb/IIIa inhibitors
42 Adjunctive Cilostazol to Dual Antiplatelet Therapy to Enhance Mobilization of Endothelial Progenitor Cell in Patients With Acute Myocardial Infarction: A Randomized, Placebo-controlled ACCEL-EPISODE Trial Unknown status NCT04407312 Phase 4 Cilostazol Tablets;placebo;Aspirin;Clopidogrel
43 Local Delivery of thrombolytIcs Before Thrombectomy in patientS With ST-elevatiOn myocardiaL Infarction Undergoing Primary percuTaneous Coronary interventION - The DISSOLUTION Randomized Trial Unknown status NCT01568931 Phase 4 Urokinase;Saline
44 A Randomized, Single-blind, Controlled Clinical Trial of Cardiomyopeptidin Intervention in Patients With Acute ST-segment Elevation Myocardial Infarction Undergoing Direct PCI After Ischemia-reperfusion Injury Unknown status NCT03958422 Phase 4 cardiomyopeptidin
45 China Tongxinluo Study for Myocardial Protection in Patients With Acute Myocardial Infarction Unknown status NCT03792035 Phase 4 Tongxinluo;Placebos
46 Erythropoietin Prevention Trial of Coronary Restenosis and Cardiac Remodeling After Acute Myocardial Infarction (EPOC-AMI) Unknown status NCT00423020 Phase 4 Erythropoietin
47 Peri-Procedural Myocardial Infarction, Platelet Reactivity, Thrombin Generation, and Clot Strength: Differential Effects of Eptifibatide + Bivalirudin Versus Bivalirudin -The CLEAR PLATELETS-2 Study Unknown status NCT00370045 Phase 4 Bivalirudin with and without eptifibatide
48 Multicentre 2x2 Factorial Randomised Study Comparing Tirofiban Administered With the Single High-Dose Bolus Versus Abciximab and Sirolimus Eluting Stent Versus Bare Metal Stent in Acute Myocardial Infarction - MULTI-STRATEGY Trial Unknown status NCT00229515 Phase 4
49 A Multi-center Study on the Optimized Antithrombotic Therapy of Acute Myocardial Infarction With Left Ventricular Mural Thrombus. Unknown status NCT03415386 Phase 4 Combination of antiplatelet drugs and anticoagulants for at least one month
50 Effects of Sodium Tanshinone IIA Sulfonate on Left Ventricular Remodeling in Patients With ST-segment Elevation Myocardial Infarction Following Percutaneous Coronary Intervention Unknown status NCT02524964 Phase 4 sodium tanshinone IIA sulfonate

Search NIH Clinical Center for Myocardial Infarction

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Acebutolol
Acebutolol Hydrochloride
alteplase
anisindione
Anistreplase
Atenolol
Bisoprolol
Bisoprolol Fumarate
carvedilol
carvedilol phosphate
Dalteparin
Dalteparin Sodium
Diltiazem
Diltiazem Hydrochloride
Diltiazem maleate
DITIAZ
Enoxaparin
eptifibatide
esmolol
Esmolol hydrochloride
heparin
heparin calcium
heparin sodium
HEPARIN SODIUM (BEEF LUNG)
heparin sodium, bovine
heparin sodium, porcine
Labetalol
Labetalol hydrochloride
LIDOCAINE HCL PWDR
Lidocaine Hydrochloride
Lisinopril
Metoprolol
metoprolol succinate
Metoprolol Tartrate
Nadolol
Nitroglycerin
Penbutolol
Penbutolol Sulfate
Pindolol
Propranolol
Propranolol Hydrochloride
Reteplase
Streptokinase
Sulfinpyrazone
Tenecteplase
Timolol
Timolol Hemihydrate
Timolol Maleate
tirofiban
TIROFIBAN HYDROCHLORIDE
Urokinase
Verapamil
Verapamil hydrochloride

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Myocardial Infarction cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Myocardial Infarction:
ADRCs, adipose-derived regenerative cells for cardiovascular disease
AMI MultiStem, bone marrow-derived cells for acute myocardial infarction
AMR-001, bone marrow-derived CD34+ cells for myocardial infarction
Autologous bone marrow-derived mononuclear cells for myocardial infarction
Bone marrow or peripheral blood-derived stem cells for treatment of myocardial ischemia
Bone marrow-derived adult mononuclear cells for heart diseases
Bone marrow-derived CD133+ vs. mononuclear cells for treatment of myocardial infarction
Bone marrow-derived mesenchymal stem cells for treatment of myocardial ischemia
Bone marrow-derived mononuclear cells for acute myocardial infarction
Bone marrow-derived mononuclear cells for chronic myocardial infarction
Bone marrow-derived mononuclear cells for myocardial infarction
Bone marrow-derived mononuclear cells for myocardial infarction
Bone marrow-derived mononuclear cells for myocardial infarction
Bone marrow-derived mononuclear cells for treatment of myocardial infarction
Bone marrow-derived progenitor cells for myocardial infarction
Bone marrow-derived stem cells for treatment of ischemic cardiomyopathy
Cardiosphere-derived autologous stem cells for reverse ventricular dysfunction
Cardiosphere-derived cells for the treatment of myocardial infarction
CD133+ bone marrow-derived stem cells in conjuction with coronary artery bypass grafting
Combination therapy of mononuclear cells with laser for coronary disease
Early endothelial progenitor cells for acute myocardial infarction
Embryonic stem cell-derived cardiomyocyte transplantation for myocardial infarction
Embryonic stem cell-derived cardiomyocytes for treatment of myocardial infarction
Enriched bone marrow-derived progenitor cells for heart diseases
Hearticellgram-AMI, mesenchymal stem cells for acute myocardial infarction
Hydrogels with cardiomyocytes for myocardial repair
Induced pluripotent stem cells for treatment of myocardial infarction
itMSC, bone marrow-derived mesenchymal stem cells for cardiovascular diseases
Mesenchymal precursor cells for cardiovascular diseases
Mesendo, stem cell combination for treatment of cardiovascular diseases
MyoCell, muscle stem cells for severe heart damage
Prochymal, mesenchymal stem cells for treatment of acute myocardial infarction
Sca-1-positive cardiac progenitor cells for treatment of myocardial infarction
Stem cell therapy for treatment of acute myocardial infarction
StempeucelAMI, mesenchymal stem cells for acute myocardial infarction
Umbilical cord blood-derived CD133 positive cells for treatment of myocardial infarction
Embryonic/Adult Cultured Cells Related to Myocardial Infarction:
Adipose-derived stem and regenerative cells PMIDs: 22281257 21082397
Bone marrow-derived adherent progenitor cells (MultiStem) PMIDs: 23111647 22004910 21175285 22052917
Bone marrow-derived autologous CD34+cells (AMR-001) PMIDs: 21167340
Bone marrow-derived mononuclear cells PMIDs: 19002124
Bone marrow-derived mononuclear cells
Peripheral blood-derived hematopoietic stem cells (family)
Bone marrow-derived mononuclear cells PMIDs: 22137069 20524773 20445812 19699857
Bone marrow-derived CD133+ hematopoietic stem cells
Bone marrow-derived mononuclear cells (family) PMIDs: 22192151 21414223 16382259 16889856 22940024 21392602
Bone marrow-derived mesenchymal stem cells (family)
Bone marrow-derived mononuclear cells
Bone marrow-derived mononuclear cells PMIDs: 22834565
Bone marrow-derived mesenchymal stem cells PMIDs: 16382259 16889856
Bone marrow-derived mononuclear cells PMIDs: 22834565
Bone marrow-derived mononuclear cells
Bone marrow-derived progenitor cells PMIDs: 20448133 18293890 16159812
Bone marrow-derived mesenchymal stem cells PMIDs: 22940024 21392602
Porcine bone marrow-derived mesenchymal stem cells PMIDs: 22940024 21392602 19958962
Cardiosphere-derived cells PMIDs: 22336189 17283259
Bone marrow-derived CD133+ cells PMIDs: 17320570
Peripheral blood-derived endothelial progenitor cells PMIDs: 22239631 21362705
eNOS-transfected endothelial progenitor cells PMIDs: 22239631 21362705
Cardiomyocyte-like cells PMIDs: 17980256 21783246
Cardiomyocyte-like cells PMIDs: 22040108
Bone marrow-derived progenitor cells PMIDs: 16990385 22651868 22936827 23362308 16990384 18794392
Neonatal rat ventricular cardiomyocytes PMIDs: 21783246
DR4 induced pluripotent stem cells PMIDs: 23568891
Mesenchymal Precursor Cells (STRO-3 selected) PMIDs: 20850099 21155976
Bone marrow-derived mononuclear cells PMIDs: 21323410 20631864
Bone marrow-derived mesenchymal stem cells PMIDs: 21323410 20631864
Skeletal myoblasts (MyoCell) PMIDs: 19051139 15615560 16446778
Bone marrow-derived mesenchymal stem cells PMIDs: 19958962
Cardiac progenitor cells (Sca1+) PMIDs: 21980409
Bone marrow-derived CD34+/CXCR4+ cells
Bone marrow-derived mesenchymal stem cells (Stempeucel) PMIDs: 18720444
Umbilical cord blood-derived CD133+ cells PMIDs: 16195418

Cochrane evidence based reviews: myocardial infarction

Genetic Tests for Myocardial Infarction

Genetic tests related to Myocardial Infarction:

# Genetic test Affiliating Genes
1 Myocardial Infarction 1 28
2 Myocardial Infarction 28
3 Myocardial Infarction, Susceptibility to 28 ESR1 F13A1 GCLC ITGB3 LTA

Anatomical Context for Myocardial Infarction

Organs/tissues related to Myocardial Infarction:

MalaCards : Heart, Bone Marrow, Bone, Endothelial, Lung, Kidney, Neutrophil
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Myocardial Infarction:
# Tissue Anatomical CompartmentCell Relevance
1 Bone Bone Marrow Bone Marrow Stromal Cells Potential therapeutic candidate
2 Limb Pelvic Girdle Bone Marrow Stromal Cells Potential therapeutic candidate
3 Heart Myocardium Cardiomyocytes Affected by disease

Publications for Myocardial Infarction

Articles related to Myocardial Infarction:

(show top 50) (show all 52016)
# Title Authors PMID Year
1
An LRP8 variant is associated with familial and premature coronary artery disease and myocardial infarction. 62 57 5
17847002 2007
2
Functional variation in LGALS2 confers risk of myocardial infarction and regulates lymphotoxin-alpha secretion in vitro. 53 62 5
15129282 2004
3
Oxidized LDL receptor gene (OLR1) is associated with the risk of myocardial infarction. 53 62 5
12646194 2003
4
Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. 53 62 5
1328889 1992
5
Dysfunctional nitric oxide signalling increases risk of myocardial infarction. 62 5
24213632 2013
6
A functional SNP in PSMA6 confers risk of myocardial infarction in the Japanese population. 62 5
16845397 2006
7
Identification of a novel non-coding RNA, MIAT, that confers risk of myocardial infarction. 62 5
17066261 2006
8
Premature myocardial infarction novel susceptibility locus on chromosome 1P34-36 identified by genomewide linkage analysis. 62 57
14732905 2004
9
Association of single nucleotide polymorphisms in the oxidised LDL receptor 1 (OLR1) gene in patients with acute myocardial infarction. 62 5
14684693 2003
10
Association of polymorphism in glutamate-cysteine ligase catalytic subunit gene with coronary vasomotor dysfunction and myocardial infarction. 62 5
12598062 2003
11
Functional SNPs in the lymphotoxin-alpha gene that are associated with susceptibility to myocardial infarction. 62 5
12426569 2002
12
Polymorphism in the 5'-flanking region of human glutamate-cysteine ligase modifier subunit gene is associated with myocardial infarction. 62 5
12081989 2002
13
Polymorphisms in the factor VII gene and the risk of myocardial infarction in patients with coronary artery disease. 62 5
10984565 2000
14
Large-scale test of hypothesised associations between the angiotensin-converting-enzyme insertion/deletion polymorphism and myocardial infarction in about 5000 cases and 6000 controls. International Studies of Infarct Survival (ISIS) Collaborators. 62 5
10841123 2000
15
Array-based multiplex analysis of candidate genes reveals two independent and additive genetic risk factors for myocardial infarction in the Finnish population. 62 5
9700201 1998
16
Association of a common polymorphism in the factor XIII gene with myocardial infarction. 62 5
9459313 1998
17
Deletion polymorphism of the angiotensin I-converting enzyme gene is associated with increased plasma angiotensin-converting enzyme activity but not with increased risk for myocardial infarction and coronary artery disease. 53 5
8644984 1996
18
A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. 62 5
8598867 1996
19
Angiotensin converting enzyme gene deletion allele is independently and strongly associated with coronary atherosclerosis and myocardial infarction. 53 5
8541160 1995
20
A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemic heart disease. 53 5
7854377 1995
21
Insertion/deletion polymorphism of the angiotensin-converting enzyme gene is strongly associated with coronary heart disease in non-insulin-dependent diabetes mellitus. 53 5
8170965 1994
22
Insertion/deletion (I/D) polymorphism at the locus for angiotensin I-converting enzyme and parental history of myocardial infarction. 53 5
8131300 1993
23
Insertion/deletion (I/D) polymorphism at the locus for angiotensin I-converting enzyme and myocardial infarction. 53 5
8131299 1993
24
Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. 62 5
1386652 1992
25
Abbreviated Antiplatelet Therapy After Coronary Stenting in Patients With Myocardial Infarction at High Bleeding Risk. 62 41
36137672 2022
26
Plasma microRNA 499 as a biomarker of acute myocardial infarction. 62 46
20395621 2010
27
MicroRNAs miR-1, miR-133a, miR-133b and miR-208 are dysregulated in human myocardial infarction. 62 46
20029200 2010
28
MicroRNA expression signature and the role of microRNA-21 in the early phase of acute myocardial infarction. 62 46
19706597 2009
29
Replication studies for the association of PSMA6 polymorphism with coronary artery disease in East Asian populations. 5
19282875 2009
30
ACE D/I polymorphism, migraine, and cardiovascular disease in women. 5
19221299 2009
31
Factor XIII Val34Leu variant and the risk of myocardial infarction: a meta-analysis. 5
17393027 2007
32
Integrin beta3 Leu33Pro polymorphism and risk of hip fracture: 25 years follow-up of 9233 adults from the general population. 5
17264806 2007
33
Angiotensin converting enzyme gene polymorphism and cardiovascular morbidity and mortality: the Rotterdam Study. 5
15635071 2005
34
Meta-analysis of genetic studies in ischemic stroke: thirty-two genes involving approximately 18,000 cases and 58,000 controls. 5
15534175 2004
35
The effects of the ACE gene insertion/deletion polymorphism on glucose tolerance and insulin secretion in elderly people are modified by birth weight. 5
15531537 2004
36
ACE1 polymorphism and progression of SARS. 5
15381116 2004
37
A trio family study showing association of the lymphotoxin-alpha N26 (804A) allele with coronary artery disease. 5
15266304 2004
38
DD genotype of ACE gene is a risk factor for intracerebral hemorrhage. 5
15277638 2004
39
A genetic variant of ACE increases cell survival: a new paradigm for biology and disease. 5
15110771 2004
40
Alzheimer disease risk and genetic variation in ACE: a meta-analysis. 5
14872014 2004
41
Association of tumor necrosis factor polymorphisms with asthma and serum total IgE. 5
14681301 2004
42
Angiotensin-converting enzyme DD genotype is associated with worse perinatal cardiorespiratory adaptation in preterm infants. 5
14657821 2003
43
Association between estrogen receptor alpha gene variation and cardiovascular disease. 5
14600184 2003
44
Polymorphism in glutamate-cysteine ligase modifier subunit gene is associated with impairment of nitric oxide-mediated coronary vasomotor function. 5
12975258 2003
45
Genetic variation in lectin-like oxidized low-density lipoprotein receptor 1 (LOX1) gene and the risk of coronary artery disease. 5
12810610 2003
46
Genetic variants of coagulation factor XIII, postmenopausal estrogen therapy, and risk of nonfatal myocardial infarction. 5
12456499 2003
47
Cytokine gene polymorphisms: association with psoriatic arthritis susceptibility and severity. 5
12746914 2003
48
Phenotype modulators in myophosphorylase deficiency. 5
12666117 2003
49
Interdependent effect of angiotensin-converting enzyme and platelet-activating factor acetylhydrolase gene polymorphisms on the progression of immunoglobulin A nephropathy. 5
12220450 2002
50
The effect of the Val34Leu polymorphism in the factor XIII gene in infants with a birth weight below 1500 g. 5
12072871 2002

Variations for Myocardial Infarction

ClinVar genetic disease variations for Myocardial Infarction:

5 (show all 22)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 F13A1 NM_000129.4(F13A1):c.103G>T (p.Val35Leu) SNV Protective
16532 rs5985 GRCh37: 6:6318795-6318795
GRCh38: 6:6318562-6318562
2 CLCN1 NM_000083.3(CLCN1):c.568_569delinsTC (p.Gly190Ser) INDEL Pathogenic
209139 rs797045032 GRCh37: 7:143018813-143018814
GRCh38: 7:143321720-143321721
3 GUCY1A1 NM_001130682.3(GUCY1A1):c.488dup (p.Leu163fs) DUP Pathogenic
65427 rs587777928 GRCh37: 4:156631799-156631800
GRCh38: 4:155710647-155710648
4 CCT7 NM_006429.4(CCT7):c.1574C>T (p.Ser525Leu) SNV Pathogenic
65429 rs587777929 GRCh37: 2:73479931-73479931
GRCh38: 2:73252803-73252803
5 F10, F7 NM_019616.4(F7):c.1172G>A (p.Arg391Gln) SNV Risk Factor
12080 rs6046 GRCh37: 13:113773159-113773159
GRCh38: 13:113118845-113118845
6 F7 NG_009262.1:g.4727_4728insCCTATATCCT INSERT Risk Factor
12079 rs5742910 GRCh37: 13:113759830-113759831
GRCh38: 13:113105516-113105517
7 ESR1 NM_000125.4(ESR1):c.453-397T>C SNV Risk Factor
16594 rs2234693 GRCh37: 6:152163335-152163335
GRCh38: 6:151842200-151842200
8 MIAT MIAT, HAPLOTYPE, TAAAAT SNV Risk Factor
1022 GRCh37:
GRCh38:
9 PSMA6 NM_002791.3(PSMA6):c.-8C>G SNV Risk Factor
6796 rs1048990 GRCh37: 14:35761675-35761675
GRCh38: 14:35292469-35292469
10 OLR1 NM_002543.4(OLR1):c.501G>C (p.Lys167Asn) SNV Risk Factor
6994 rs11053646 GRCh37: 12:10313448-10313448
GRCh38: 12:10160849-10160849
11 OLR1 NM_002543.4(OLR1):c.*188= SNV Risk Factor
6995 rs12316150 GRCh37: 12:10312291-10312291
GRCh38: 12:10159692-10159692
12 GCLM NG_012072.1:g.4704C>T SNV Risk Factor
8366 GRCh37: 1:94375309-94375309
GRCh38: 1:93909753-93909753
13 ITGB3 NM_000212.3(ITGB3):c.176T>C (p.Leu59Pro) SNV Risk Factor
13558 rs5918 GRCh37: 17:45360730-45360730
GRCh38: 17:47283364-47283364
14 LTA NM_000595.4(LTA):c.179C>A (p.Thr60Asn) SNV Risk Factor
14379 rs1041981 GRCh37: 6:31540784-31540784
GRCh38: 6:31573007-31573007
15 LTA, LOC100287329 NM_000595.4(LTA):c.-10+90A>G SNV Risk Factor
14380 rs909253 GRCh37: 6:31540313-31540313
GRCh38: 6:31572536-31572536
16 LGALS2 NM_006498.3(LGALS2):c.6+3279C>T SNV Risk Factor
14472 rs7291467 GRCh37: 22:37972628-37972628
GRCh38: 22:37576621-37576621
17 ACE NM_000789.3(ACE):c.2306-117_2306-116insAF118569.1:g.14094_14382 INSERT Risk Factor
18061 GRCh37: 17:61565892-61565893
GRCh38: 17:63488531-63488532
18 GCLC NM_001498.4(GCLC):c.-594C>T SNV Risk Factor
439753 rs17883901 GRCh37: 6:53410037-53410037
GRCh38: 6:53545239-53545239
19 LRP8 NM_004631.5(LRP8):c.2855G>A (p.Arg952Gln) SNV Risk Factor
6996 rs5174 GRCh37: 1:53712727-53712727
GRCh38: 1:53247055-53247055
20 APOC3 NM_000040.3(APOC3):c.*40G>C SNV Uncertain Significance
1250845 GRCh37: 11:116703640-116703640
GRCh38: 11:116832924-116832924
21 ABCC9 NM_020297.4(ABCC9):c.2200G>A (p.Val734Ile) SNV Benign
35627 rs61688134 GRCh37: 12:22017410-22017410
GRCh38: 12:21864476-21864476
22 ACE NM_000789.4(ACE):c.2328G>A (p.Thr776=) SNV Benign
256803 rs4343 GRCh37: 17:61566031-61566031
GRCh38: 17:63488670-63488670

Expression for Myocardial Infarction

Search GEO for disease gene expression data for Myocardial Infarction.

Pathways for Myocardial Infarction

Pathways related to Myocardial Infarction according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.49 OLR1 LRP8 ITGB3 GUCY1A1 F7 F13A1
2 10.28 GUCY1A1 GCLM GCLC

GO Terms for Myocardial Infarction

Cellular components related to Myocardial Infarction according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 glutamate-cysteine ligase complex GO:0017109 8.92 GCLM GCLC

Biological processes related to Myocardial Infarction according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to nutrient GO:0007584 9.95 LTA GCLM GCLC
2 response to activity GO:0014823 9.93 ITGB3 GCLM GCLC
3 positive regulation of cell migration GO:0030335 9.8 CDKN2B-AS1 F7 ITGB3 MIR21 MIR210
4 regulation of mitochondrial depolarization GO:0051900 9.67 GCLM GCLC
5 negative regulation of regulatory T cell differentiation GO:0045590 9.61 TNFSF4 MIR21
6 response to nitrosative stress GO:0051409 9.56 GCLM GCLC
7 cysteine metabolic process GO:0006534 9.46 GCLM GCLC
8 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.4 MIR210 MIR21
9 response to human chorionic gonadotropin GO:0044752 9.26 GCLM GCLC
10 cellular response to thyroxine stimulus GO:0097069 8.92 GCLM GCLC

Molecular functions related to Myocardial Infarction according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 glutamate-cysteine ligase activity GO:0004357 8.92 GCLM GCLC

Sources for Myocardial Infarction

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 24-Oct-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....